1.Kato K, Cho BC, Takahashi M, Okada M, Lin CY, Chin K et al. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION–3): a multicentre, randomised, open-label, phase 3 trial. The Lancet Oncology 2019; 20(11):1506–17.
2.Carbone DP, Reck M, Paz-Ares L, Creelan B, Horn L, Steins M et al. First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer. N Engl J Med 2017; 376(25):2415–26.
3.Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L et al. Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. N Engl J Med 2017; 376(11):1015–26.
4.Chen L. Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol 2004; 4(5):336–47.
5.Huang X, Venet F, Wang YL, Lepape A, Yuan Z, Chen Y et al. PD–1 expression by macrophages plays a pathologic role in altering microbial clearance and the innate inflammatory response to sepsis. Proc Natl Acad Sci U S A 2009; 106(15):6303–8.
6.Bally AP, Lu P, Tang Y, Austin JW, Scharer CD, Ahmed R et al. NF-kappaB regulates PD–1 expression in macrophages. J Immunol 2015; 194(9):4545–54.
7.Chen W, Wang J, Jia L, Liu J, Tian Y. Attenuation of the programmed cell death–1 pathway increases the M1 polarization of macrophages induced by zymosan. Cell death & disease 2016; 7:e2115.
8.Shen L, Gao Y, Liu Y, Zhang B, Liu Q, Wu J et al. PD–1/PD-L pathway inhibits M.tb-specific CD4(+) T-cell functions and phagocytosis of macrophages in active tuberculosis. Scientific reports 2016; 6:38362.
9.Gordon SR, Maute RL, Dulken BW, Hutter G, George BM, McCracken MN et al. PD–1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. Nature 2017; 545(7655):495–9.
10.Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68(6):394–424.
11.Saito H, Kuroda H, Matsunaga T, Osaki T, Ikeguchi M. Increased PD–1 expression on CD4+ and CD8+ T cells is involved in immune evasion in gastric cancer. Journal of surgical oncology 2013; 107(5):517–22.
12.Kang YK, Boku N, Satoh T, Ryu MH, Chao Y, Kato K et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO–4538–12, ATTRACTION–2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet (London, England) 2017; 390(10111):2461–71.
13.Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer 2011; 14(2):101–12.
14.Murakami Y, Saito H, Shimizu S, Kono Y, Shishido Y, Miyatani K et al. Increased regulatory B cells are involved in immune evasion in patients with gastric cancer. Scientific reports 2019; 9(1):13083.
15.Ruifrok AC, Johnston DA. Quantification of histochemical staining by color deconvolution. Analytical and quantitative cytology and histology 2001; 23(4):291–9.
16.Miyatani K, Saito H, Murakami Y, Watanabe J, Kuroda H, Matsunaga T et al. A high number of IgG4-positive cells in gastric cancer tissue is associated with tumor progression and poor prognosis. Virchows Archiv: an international journal of pathology 2016; 468(5):549–57.
17.Ishida Y, Agata Y, Shibahara K, Honjo T. Induced expression of PD–1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. The EMBO journal 1992; 11(11):3887–95.
18.Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H et al. Engagement of the PD–1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000; 192(7):1027–34.
19.Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, Sharpe AH et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 2006; 439(7077):682–7.
20.Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD–1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008; 26:677–704.
21.Matsuzaki J, Gnjatic S, Mhawech-Fauceglia P, Beck A, Miller A, Tsuji T et al. Tumor-infiltrating NY-ESO–1-specific CD8+ T cells are negatively regulated by LAG–3 and PD–1 in human ovarian cancer. Proc Natl Acad Sci U S A 2010; 107(17):7875–80.
22.Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S. Functions of natural killer cells. Nat Immunol 2008; 9(5):503–10.
23.Liu Y, Cheng Y, Xu Y, Wang Z, Du X, Li C et al. Increased expression of programmed cell death protein 1 on NK cells inhibits NK-cell-mediated anti-tumor function and indicates poor prognosis in digestive cancers. Oncogene 2017; 36(44):6143–53.
24.Xiao X, Lao XM, Chen MM, Liu RX, Wei Y, Ouyang FZ et al. PD–1hi Identifies a Novel Regulatory B-cell Population in Human Hepatoma That Promotes Disease Progression. Cancer discovery 2016; 6(5):546–59.
25.Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends in immunology 2002; 23(11):549–55.
26.Murray PJ, Allen JE, Biswas SK, Fisher EA, Gilroy DW, Goerdt S et al. Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity 2014; 41(1):14–20.
27.Heusinkveld M, van der Burg SH. Identification and manipulation of tumor associated macrophages in human cancers. Journal of translational medicine 2011; 9:216.
28.Sica A, Schioppa T, Mantovani A, Allavena P. Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. European journal of cancer (Oxford, England: 1990) 2006; 42(6):717–27.
29.Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 2004; 4(1):71–8.
30.Saito H, Kono Y, Murakami Y, Shishido Y, Kuroda H, Matsunaga T et al. Highly Activated PD–1/PD-L1 Pathway in Gastric Cancer with PD-L1 Expression. Anticancer research 2018; 38(1):107–12.